Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia. The company's products also comprise SPK-7001 that is in Phase 1/2 trial for choroideremia; SPK-9001, which is in Phase 1/2 trial for hemophilia B; and SPK-8011 that is in Phase 1/2 trial hemophilia A. In addition, its product candidates and development programs include SPK-FVIII program to treat hemophilia A; SPK-TPP1 program for the treatment of CLN2 disease; RhoNova for the treatment of rhodopsin-linked autosomal dominant retinitis pigmentosa; and other neurodegenerative diseases. The company has collaboration agreement with Pfizer, Inc. for the development and commercialization of SPK-FIX product candidates in its gene therapy program for the treatment of hemophilia B. Spark Therapeutics, Inc. was founded in 2013 and is headquartered in Philadelphia, Pennsylvania.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ONCE
CUSIPN/A
Phone888-772-7560
Debt
Debt-to-Equity RatioN/A
Current Ratio18.48
Quick Ratio18.14
Price-To-Earnings
Trailing P/E Ratio-7.48
Forward P/E Ratio-32.83
P/E GrowthN/A
Sales & Book Value
Annual Sales$12.07 million
Price / Sales169.64
Cash FlowN/A
Price / CashN/A
Book Value$13.88 per share
Price / Book3.93
Profitability
EPS (Most Recent Fiscal Year)($7.63)
Net Income$-253,480,000.00
Net Margins-185.46%
Return on Equity-17.33%
Return on Assets-13.83%
Miscellaneous
Employees315
Outstanding Shares37,570,000
Market Cap$2.13 billion
Spark Therapeutics (NASDAQ:ONCE) Frequently Asked Questions
What is Spark Therapeutics' stock symbol?
Spark Therapeutics trades on the NASDAQ under the ticker symbol "ONCE."
How were Spark Therapeutics' earnings last quarter?
Spark Therapeutics Inc (NASDAQ:ONCE) issued its quarterly earnings results on Tuesday, August, 7th. The biotechnology company reported ($0.77) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.43) by $0.34. The biotechnology company earned $25.19 million during the quarter, compared to analysts' expectations of $29.44 million. Spark Therapeutics had a negative return on equity of 17.33% and a negative net margin of 185.46%. View Spark Therapeutics' Earnings History.
When is Spark Therapeutics' next earnings date?
What price target have analysts set for ONCE?
21 Wall Street analysts have issued 1 year target prices for Spark Therapeutics' shares. Their predictions range from $40.00 to $103.00. On average, they anticipate Spark Therapeutics' share price to reach $72.15 in the next year. This suggests a possible upside of 29.6% from the stock's current price. View Analyst Price Targets for Spark Therapeutics.
What is the consensus analysts' recommendation for Spark Therapeutics?
21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spark Therapeutics in the last year. There are currently 2 sell ratings, 8 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Spark Therapeutics.
What are Wall Street analysts saying about Spark Therapeutics stock?
Here are some recent quotes from research analysts about Spark Therapeutics stock:
- 1. Mizuho analysts commented, "We further think it is pre-mature to draw the conclusion that SPK-8011 is inferior to the competing product from BioMarin (BMRN, non-rated). We reduce our PT from $91 to $77 after removing the M&A premium of our valuation per revised valuation methodology and we maintain our revenue forecasts." (8/8/2018)
- 2. Cantor Fitzgerald analysts commented, ": We reiterate our Overweight rating and 12-month PT of $103 on 2Q18 financial results and program updates. During the call, Spark announced additional updates from the Phase 1/2 trial of SPK-8011 in hemophilia A. While the occurrence of two immune responses leading to inadequate FVIII activity level add challenges for the program, we believe the company is well equipped to address them as the program moves to late-stage development." (8/7/2018)
- 3. Raymond James analysts commented, "We are maintaining our Outperform rating for Spark. Hemophilia (WFH) 2018 World Congress, the company, along with its partner, Pfizer, provided an update on the ongoing Phase I/II study evaluating SPK-9001 for hemophilia B (Hem B). In addition, Spark’s competitor, BioMarin, provided an update on the ongoing Phase I/II trial of valoctocogene roxaparvovec (or BMN 270) in severe hemophilia A (Hem A)." (5/23/2018)
Who are some of Spark Therapeutics' key competitors?
Some companies that are related to Spark Therapeutics include AveXis (AVXS), bluebird bio (BLUE), BIO-TECHNE (TECH), Ablynx (ABLYF), China Biologic Products (CBPO), Acceleron Pharma (XLRN), argenx (ARGX), Aerie Pharmaceuticals (AERI), Repligen (RGEN), Crispr Therapeutics (CRSP), Halozyme Therapeutics (HALO), Regenxbio (RGNX), Momenta Pharmaceuticals (MNTA), Denali Therapeutics (DNLI) and Atara Biotherapeutics (ATRA).
Who are Spark Therapeutics' key executives?
Spark Therapeutics' management team includes the folowing people:
- Mr. Jeffrey D. Marrazzo, Co-Founder, CEO & Director (Age 39)
- Dr. Katherine A. High, Co-Founder, Pres, Head of R&D and Director (Age 66)
- Mr. Stephen W. Webster, Chief Financial Officer (Age 57)
- Mr. Joseph W. La Barge Esq., J.D., Chief Legal Officer & Sec. (Age 47)
- Mr. Daniel R. Faga, Chief Bus. Officer (Age 38)
When did Spark Therapeutics IPO?
(ONCE) raised $88 million in an initial public offering on Friday, January 30th 2015. The company issued 5,500,000 shares at $15.00-$17.00 per share. J.P. Morgan and Credit Suisse acted as the underwriters for the IPO and Cowen and Company and Sanford C. Bernstein were co-managers.
Has Spark Therapeutics been receiving favorable news coverage?
Headlines about ONCE stock have trended somewhat positive recently, according to Accern. The research group identifies negative and positive press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Spark Therapeutics earned a media and rumor sentiment score of 0.18 on Accern's scale. They also assigned news articles about the biotechnology company an impact score of 46.57 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near term. View Recent Headlines for Spark Therapeutics.
Who are Spark Therapeutics' major shareholders?
Spark Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (14.74%), BlackRock Inc. (7.67%), Federated Investors Inc. PA (4.08%), Partner Fund Management L.P. (2.33%), Gilder Gagnon Howe & Co. LLC (1.41%) and Morgan Stanley (1.23%). Company insiders that own Spark Therapeutics stock include Anand Mehra, Barge Joseph La, Daniel Faga, Hospital Of Philade Children's, Jeffrey D Marrazzo, John Furey, Katherine A High and Stephen W Webster. View Institutional Ownership Trends for Spark Therapeutics.
Which institutional investors are selling Spark Therapeutics stock?
ONCE stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Pinnacle Associates Ltd., Macquarie Group Ltd., Wells Fargo & Company MN, Sector Gamma AS, TD Asset Management Inc., Alps Advisors Inc. and Massachusetts Financial Services Co. MA. Company insiders that have sold Spark Therapeutics company stock in the last year include Barge Joseph La, Daniel Faga, Hospital Of Philade Children's, Jeffrey D Marrazzo, John Furey, Katherine A High and Stephen W Webster. View Insider Buying and Selling for Spark Therapeutics.
Which institutional investors are buying Spark Therapeutics stock?
ONCE stock was bought by a variety of institutional investors in the last quarter, including Partner Fund Management L.P., BlackRock Inc., FMR LLC, Millennium Management LLC, Morgan Stanley, Renaissance Technologies LLC, American Century Companies Inc. and Northern Trust Corp. View Insider Buying and Selling for Spark Therapeutics.
How do I buy shares of Spark Therapeutics?
Shares of ONCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Spark Therapeutics' stock price today?
One share of ONCE stock can currently be purchased for approximately $55.67.
How big of a company is Spark Therapeutics?
Spark Therapeutics has a market capitalization of $2.13 billion and generates $12.07 million in revenue each year. The biotechnology company earns $-253,480,000.00 in net income (profit) each year or ($7.63) on an earnings per share basis. Spark Therapeutics employs 315 workers across the globe.
How can I contact Spark Therapeutics?
Spark Therapeutics' mailing address is 3737 MARKET STREET SUITE 1300, PHILADELPHIA PA, 19104. The biotechnology company can be reached via phone at 888-772-7560 or via email at [email protected]
MarketBeat Community Rating for Spark Therapeutics (NASDAQ ONCE)
MarketBeat's community ratings are surveys of what our community members think about Spark Therapeutics and other stocks. Vote "Outperform" if you believe ONCE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONCE will underperform the S&P 500 over the long term. You may vote once every thirty days.
